BellaSeno scoops German Innovation Award for its breast reconstruction technology

BellaSeno, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, has received the German Innovation Award from the German Design Council for its Senella technology in the category #W2 Excellence in Business to Business — Medical Technologies. BellaSeno has been chosen among about 700 applicants from 30 countries, covering bluechip and innovative start-up companies. 

Senella has been designed to alleviate the complications and risks found in current breast reconstruction and augmentation approaches. Based on a patented porous scaffold made of an absorbable biocompatible polymer that is FDA-approved and CE-marked for a variety of clinical applications and used routinely in the clinic for over 30 years, Senella is absorbed over a span of 2 years. The clinical end result is a natural soft tissue, without remnants of foreign material.

Senella is currently being developed for breast reconstruction and the rare chest defect pectus excavatum. First-in-human trials are ongoing.

Mohit Chhaya, co-founder and CEO of BellaSeno said: "The award is an important recognition of our work in the field of natural tissue reconstruction. Our goal is to provide patients and surgeons with safer, more natural alternatives to standard breast reconstruction approaches, ultimately leading to a restoration of the natural breast."